antiphospholipid syndrome

History of Thrombosis and Hematologic Disease Double the Risk of New Clots in Persistently aPL‑Positive Patients: Prospective APS ACTION Registry Analysis

By MedXY 12/05/2025

In 1,067 persistently antiphospholipid antibody–positive patients followed for 4,727 person‑years, prior thrombosis and coexistent hematologic disease each conferred ~2‑fold increased risk for new thrombosis; microvascular disease and obesity showed trends.

news Rheumatology

EAPSDAS: The First EULAR Disease Activity Score for Antiphospholipid Syndrome — What Clinicians Need to Know

By MedXY 12/04/2025

EULAR’s new antiphospholipid syndrome disease activity score (EAPSDAS) provides the first standardized, validated tool to measure APS activity across thrombotic, microvascular and obstetric manifestations — a major advance for clinical care and trials.

Cardiology news Rheumatology

High Cardiovascular Risk but Poor Risk-factor Control in Antiphospholipid Syndrome — Worse in Primary APS than SLE-related APS

By MedXY 11/30/2025

A multinational cross-sectional study of 1003 people with antiphospholipid syndrome (APS) found high prevalence of hypertension, hyperlipidaemia, obesity and smoking, with suboptimal attainment of guideline targets — particularly among those with primary APS.

Clinical Updates news OB/GYN & Women's Health Specialties

Certolizumab Pegol Shows Promise in Reducing Adverse Pregnancy Outcomes in High-Risk APS Patients: Insights from the IMPACT Trial

By MedXY 09/19/2025

The IMPACT trial demonstrates that adding certolizumab pegol to standard therapy reduces placenta-mediated adverse pregnancy outcomes in women with antiphospholipid syndrome and lupus anticoagulant, with favorable safety and neonatal outcomes.